Abbott 2007 Annual Report : Financial Report : Financial Review (4)

Contractual Obligations

The following table summarizes Abbott's estimated contractual obligations as of December 31, 2007:

(dollars in millions)	Payment Due By Period
	Total	2008	2009-2010	2011-2012	2013 and Thereafter
Long-term debt, including current maturities and future interest payments	$14,831	$1,365	$2,052	$3,722	$7,692
Operating lease obligations	434	87	131	87	129
Capitalized auto lease obligations	78	26	52	—	—
Purchase commitments (a)	3,551	3,194	283	67	7
Other long-term liabilities reflected on the consolidated balance sheet—
Benefit plan obligations	2,192	—	325	362	1,505
Other	1,100	—	742	115	243
Total	$22,186	$4,672	$3,585	$4,353	$9,576

(a) Purchase commitments are for purchases made in the normal course of business to meet operational and capital expenditure requirements.

Contingent Obligations

Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. In addition, Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events. In connection with the acquisition of Guidant's vascular intervention and endovascular solutions businesses, Abbott will pay to Boston Scientific $250 million each upon government approvals to market the Xience V drug-eluting stent in the U.S. and in Japan. Government approvals are anticipated in 2008 for the U.S. and in 2009 for Japan. In addition, Abbott has retained liabilities for taxes on income prior to the spin-off of Hospira and certain potential liabilities, if any, related to alleged improper pricing practices in connection with federal, state and private reimbursement for certain drugs.